Kyushu University Academic Staff Educational and Research Activities Database
List of Papers
Eiji Kashiwagi Last modified date:2021.06.03

Assistant Professor / Surgery / Urology / Kyushu University Hospital


Papers
1. Kashiwagi E, Shiota M, Masaoka H, Imada K, Monji K, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:, Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer., Prostate Int , 8 (1) :22-26, 2020, 2020.03.
2. Ide H, Mizushima T, Jiang G, Goto T, Nagata Y, Teramoto Y, Inoue S, Li Y, Kashiwagi E, Baras AS, Netto GJ, Kawahara T, Miyamoto H:, FOXO1 as a tumor suppressor inactivated via AR/ERβ signals in urothelial cells., Endocr Relat Cancer, 2020.02.
3. Kashiwagi E, Shiota M, Imada K, Monji K, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:, Relationship between body composition and hormone sensitivity for androgen deprivation therapy in metastatic prostate cancer patients., Prostate international in press,2019, 2020.03.
4. Ide H, Inoue S, Mizushima T, Kashiwagi E, Zheng Y, Miyamoto H:, Role of glucocorticoid signaling in urothelial tumorigenesis: Inhibition by prednisone presumably through inducing glucocorticoid receptor transrepression., Mol Carcinog , 58 (12): 2297-2305, 2019, 2019.12.
5. Hirata Y, Shiota M, Kobayashi T, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:, Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer., Prostate Int, 7 (4): 166-170, 2019, 2019.12.
6. Shiota M, Kobayashi T, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:, Prognostic significance of antihypertensive agents in men with castration-resistant prostate cancer., Urol Oncol , 37 (11): 813.e21-813.e26, 2019, 2019.11.
7. Shiota M, Kobayashi T, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:, Prognostic significance of antihypertensive agents in men with castration-resistant prostate cancer., Urol Oncol , 37 (11): 813.e21-813.e26, 2019, 2019.11.
8. Kashiwagi E, Imada K, Monji K, Takeuchi A, Shiota M, Inokuchi J, Tatsugami K, Eto M:, Psoas muscle volume is correlated with sexual activity and erectile dysfunction among patients with localised prostate cancer., Andrologia , 51 (9): e13354, 2019, 2019.10.
9. Tanegashima T, Togashi Y, Azuma K, Kawahara A, Ideguchi K, Sugiyama D, Kinoshita F, Akiba J, Kashiwagi E, Takeuchi A, Irie T, Tatsugami K, Hoshino T, Eto M, Nishikawa H:, Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity., Clin Cancer Res , 25 (15): 4808-4819, 2019, 2019.08.
10. Shiota M, Ushijima M, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Eto M:, Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy., Prostate, 79 (10): 1147-1155, 2019, 2019.07.
11. Kobayashi T, Namitome R, Hirata YU, Shiota M, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Eto M:, Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With De Novo Metastatic Prostate Cancer., Anticancer Res 39 (6): 3191-3195, 2019, 2019.06.
12. Shiota M, Fujimoto N, Tsukahara S, Ushijima M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Eto M:, Genetic Polymorphism in Sex Hormone-binding Globulin With a Prognosis of Androgen Deprivation Therapy in Metastatic Prostate Cancer Among Japanese Men., Clin Genitourin Cancer, 17 (3): e387-e393, 2019, 2019.06.
13. Shiota M, Fujimoto N, Tsukahara S, Ushijima M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Eto M:, The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men., Cancer Chemother Pharmacol, 83 (5): 933-938, 2019, 2019.05.
14. Shiota M, Fujimoto N, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J,Tatsugami K, Kajioka S, Uchiumi T, Eto M: , Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy., Front Oncol , 8: 635, 2018
, 2018.12.
15. Murakami T, Otsubo S, Namitome R, Shiota M, Inokuchi J, Takeuchi A, Kashiwagi E, Tatsugami K, Eto M:, Clinical factors affecting perioperative outcomes in robot-assisted radical prostatectomy., Mol Clin Oncol, 9 (5): 575-581, 2018, 2018.11.
16. Akitake N, Shiota M, Obata H, Takeuchi A, Kashiwagi E, Imada K, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M:, Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone., Prostate Int , 6 (3): 104-109,2018, 2018.09.
17. Tanaka K, Yanagihara T, Ikematsu Y, Inoue H, Ota K, Kashiwagi E, Suzuki K, Hamada N, Takeuchi A, Tatsugami K, Eto M, Ijichi K, Oda Y, Otsubo K, Yoneshima Y, Iwama E, Nakanishi Y, Okamoto I:, Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade., Oncotarget , 9 (55): 30587-30593, 2018, 2018.07.
18. Shiota M, Kashiwagi E, Murakami T, Takeuchi A, Imada K, Inokuchi J, Tatsugami K, Eto M:, Serum testosterone before and during androgen-deprivation therapy, and prognosis between cigarette smokers and nonsmokers with metastatic prostate cancer., Andrologia , 50 (10): e13119, 2018, 2019.06.
19. Shiota M, Dejima T,Yamamoto Y, Takeuchi A, Imada K, Kashiwagi E, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M:, Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants., Cancer Sci , 109 (10): 3224-3234, 2018, 2018.10.
20. Murakami T, Obata H, Akitake N, Shiota M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Eto M:, Prognostic and Predictive Factors for Anti-androgen Withdrawal in Castration-resistant Prostate Cancer., Anticancer Res, 38 (7): 4115-4121, 2018, 2018.07.
21. Shiota M, Fujimoto N, Higashijima K, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M:, Mineralocorticoid receptor signaling affects therapeutic effect of enzalutamide., Prostate in press, 2018 , 2018.05.
22. Li P, Chen J, Kashiwagi E, Mizushima T, Han B, Inoue S, Ide H, Izumi K, Miyamoto H:, The interaction between androgen receptor and semenogelin I: a synthetic LxxLL peptide antagonist inhibits the growth of prostate cancer cells., Br J Cancer, 118 (3): 416-420, 2018, 2018.02.
23. Shiota M, Fujimoto N, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Yokomizo A, Kajioka S, Uchiumi T, Eto M:, The Association of Polymorphisms in the Gene Encoding Gonadotropin-Releasing Hormone with Serum Testosterone Level during Androgen Deprivation Therapy and Prognosis of Metastatic Prostate Cancer., J Urol , 199 (3): 734-740, 2018, 2018.03.
24. Kashiwagi E, Inoue S, Mizushima T, Chen J, Ide H, Kawahara T, Reis LO, Baras AS, Netto GJ, Miyamoto H:, Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression., Br J Cancer, 118 (2): 213-223, 2018, 2018.01.
25. Shiota M, Fujimoto N, Yokomizo A, Takeuchi A, Eiji Kashiwagi, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M, The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism., Prostate Cancer Prostatic Dis , 19 (2): 191-196, 2016, 2016.06.
26. Itsumi M, Shiota M, Takeuchi A, Eiji Kashiwagi, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Naito S, Eto M, Yokomizo A, Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2., Cancer Sci , 107 (7): 1022-1028, 2016, 2016.06.
27. Takeuchi A, Eto M, Tatsugami K, Shiota M, Yamada H, Kamiryo Y, Dejima T, Eiji Kashiwagi, Inokuchi J, Ryosuke Takahashi, Yokomizo A, Ohara N, Yoshikai Y, Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer., Int Immunopharmacol, 35: 327-331, 2016, 2016.04.
28. Kashiwagi E, Izumi H, Yasuniwa Y, Baba R, Doi Y, Kidani A, Arao T, Nishio K, Naito S, Kohno K:, Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines., Cancer Sci, 102, 2, 382-386, 2011.02.